Trade-offs from a family perspective: considerations in choosing between omalizumab and complementary alternative medicine for pediatric severe asthma

Trade-offs from a family perspective: considerations in choosing between omalizumab and complementary alternative medicine for pediatric severe asthma

The management of pediatric severe asthma poses significant challenges for families. When faced with the choice between targeted biologics like omalizumab and widely used complementary alternative medicine (CAM), families navigate a complex decision-making process influenced by multiple factors. Thi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hang Chen, Yan Xu, Jian-Li Qiu, Zhi-Wei Guan, Mu-Mu Wei, Yi Zhang, Ji-Xiang Xu, Hong-Tao Cui
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Pharmacology
Subjects:	pediatric severe asthma family perspective omalizumab complementary alternative medicine (CAM) treatment decision-making risk perception
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1621101/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients
by: A. Arrobas, et al.
Published: (2021-03-01)

Drug survival of omalizumab in atopic asthma: Impact of clinical and genetic variables
by: Susana Rojo-Tolosa, et al.
Published: (2025-12-01)

Omalizumab controls surface phenotypes of dendritic cells and monocytes in asthma
by: Agnes Yang, BS, et al.
Published: (2025-08-01)

A Pharmaco-Economic Analyzis of Treating Severe Uncontrolled Child Asthma with Omalizumab — Actual Russian Clinical Practice Data
by: A. S. Kolbin, et al.
Published: (2016-11-01)

Comparative Analysis of ICS Combined with LABA versus Addition of Omalizumab on Transcriptomic Expression Profiles in Patients with Allergic Asthma
by: Liang YR, et al.
Published: (2025-06-01)

Factors Influencing Relapse After Omalizumab in Chronic Urticaria. Does the Method of Discontinuation Influence Relapse?
by: Petek Üstün, et al.
Published: (2025-07-01)

Effectiveness and pharmacoeconomic analysis of the treatment of severe asthma with omalizumab in clinical practice
by: Eva Martínez-Moragón, et al.
Published: (2019-05-01)

Omalizumab en dermatología
by: Victoria Lucía Dávila, et al.
Published: (2019-08-01)

ECONOMIC ASPECTS OF APPLICATION OF THE RUSSIAN BIOSIMILAR OMALIZUMAB IN PATIENTS WITH ATOPIC BRONCHIAL ASTHMA OF MODERATE TO SEVERE CLINICAL COURSES
by: V. S. Krysanova, et al.
Published: (2021-08-01)

Four-week IgE/baseline IgE ratio combined with tryptase predicts clinical outcome in omalizumab-treated children with moderate-to-severe asthma
by: Lu Min, et al.
Published: (2025-05-01)

Health care resource utilization of patients with asthma and food allergy initiating omalizumab
by: John A. Bird, MD, et al.
Published: (2025-08-01)

Advances in omalizumab treatment for IgE-mediated food allergies
by: Siqi WANG, et al.
Published: (2025-08-01)

Case Report: Omalizumab-associated hair loss: a case of eyebrow alopecia areata, literature review and FAERS database analysis
by: Qian Wang, et al.
Published: (2025-06-01)

Severe case of bullous pemphigoid associated with nivolumab responsive to combination therapy with dupilumab and omalizumab
by: Liana Victory, MB, BCh, BAO, MRCPI, et al.
Published: (2025-03-01)

Efficiency of Adding Omalizumab to Standard Therapy for Children with Recurrent Spontaneous Urticaria: Comparative Observational Study
by: Vera G. Kalugina, et al.
Published: (2020-08-01)

Treatment of patients with evidence of mast cell-mediated itch in the absence of hives with omalizumab
by: Kelsey L. Auyeung, et al.
Published: (2024-12-01)

Comparison of long term efficacy and cost-effectiveness of omalizumab in 150 mg and 300 mg doses in patients with chronic spontaneous urticaria
by: Fikriye Kalkan, et al.
Published: (2025-03-01)

The use of complementary and alternative medicine among cancer patients in Hawaii
by: April Hamachi, et al.
Published: (2025-05-01)

GA2LEN ANACARE consensus statement: Potential of omalizumab in food allergy management
by: Torsten Zuberbier, et al.
Published: (2024-11-01)

Rapid food desensitization associated with omalizumab before oral immunotherapy
by: Bruna Giavina-Bianchi, MD, et al.
Published: (2025-02-01)

Omalizumab treatment can increase the serum levels of vitamin D in patients with chronic spontaneous urticaria
by: MENG Zhen, et al.
Published: (2025-03-01)

Real-world clinical utility (effectiveness) of omalizumab as add-on therapy in patient with difficult-to-treat severe allergic asthma
by: Rowshne Jahan, et al.
Published: (2025-01-01)

Omalizumab in Food Allergy in Children: Current Evidence and Future Perspectives
by: Cristiana Indolfi, et al.
Published: (2025-04-01)

Clinical Efficacy and Safety of Combined House Dust mite Subcutaneous Immunotherapy and Omalizumab in Five Cases of Allergic Rhinitis and Asthma
by: P.C. Kathuria, et al.
Published: (2021-07-01)

Case Report: Omalizumab combined with voriconazole for the treatment of ABPA complicating IPA: a case report
by: Tingrui Zhao, et al.
Published: (2025-07-01)

The Long-Term Omalizumab Therapy in Children with Severe Persistent Uncontrolled Asthma: Evaluation of the Outcomes According to the Data of the Hospital Patient Registry
by: Elena A. Vishneva, et al.
Published: (2018-05-01)

Efficacy of ABC-X model care intervention combined with omalizumab on moderate to severe allergic asthma and negative emotional of family members
by: ZHAO Nina, et al.
Published: (2024-06-01)

Omalizumab is ineffective in regulating proasthmatic serum cytokine and chemokine levels in nonresponders with high BMI
by: Agnes Yang, BS, et al.
Published: (2025-05-01)

Successful Treatment of Immune Checkpoint Inhibitor–Induced Bullous Pemphigoid with Omalizumab: A Case Report and Review of the Literature
by: Chen J, et al.
Published: (2024-12-01)

Monitoring in clinical trials of complementary and alternative medicine
by: So-Young Jung, et al.
Published: (2021-06-01)

College students' communication about complementary and alternative medicine practices
by: Heather J. Carmack, et al.
Published: (2018-05-01)

Progress in the application of omalizumab in the treatment of chronic inducible urticaria
by: CHEN Ziyan, et al.
Published: (2024-12-01)

A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database
by: Yongfu Song, et al.
Published: (2025-03-01)

Eosinophilic cationic protein and D-Dimer are potential biomarkers to predict response to antihistamines but not to omalizumab in chronic spontaneous urticaria
by: Özge Atik, et al.
Published: (2024-12-01)

Does anxiety influence the use of complementary or alternative medicine among cancer patients?
by: Caroline Heyder, et al.
Published: (2025-03-01)

Results of Therapy Including Omalizumab in Adolescents With Recurrent Urticaria: Retrospective Cohort Study
by: Vera G. Kalugina, et al.
Published: (2019-09-01)

Assessing the Quality of Life Using the Health Utilities Index Questionnaire in Children With Severe Persistent Asthma During the Treatment With Omalizumab
by: Leyla S. Namazova-Baranova, et al.
Published: (2017-12-01)

Lichen planus pemphigoides treated with a low dose of oral prednisolone and omalizumab
by: Yurie Matsuura, MD, et al.
Published: (2024-11-01)

Steroid-Sparing Effect of Omalizumab in Stage IV (Corticosteroid Dependent) Allergic Bronchopulmonary Aspergillosis
by: P. C. Kathuria, et al.
Published: (2020-04-01)

Acute Motor Conduction Block Neuropathy After Initiation of Omalizumab: Case Report and Literature Review for Possible Causality
by: Hosna S. Elshony, et al.
Published: (2024-09-01)